ARC Therapeutics Launched to Develop CDK Inhibitors for the Treatment of Advanced and Resistant Cancers
“The clinical success of CDK4/6 inhibitors demonstrates the practice-changing outcomes that can be achieved by therapeutically targeting specific CDK family members,” said Patrick Roberts, Ph.D., Pharm.D., Chief Executive Officer and Co-Founder of ARC Therapeutics. “CDK2 is a known driver of abnormal cancer cell proliferation and is an important therapeutic target of unmet need. Our team is excited to apply its knowledge and expertise in developing potent and selective CDK inhibitors toward the development of a CDK2 inhibitor that has significant promise to advance the current standard of care for people living with cancer.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.